GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Allist Pharmaceuticals Co 688578.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

85.10

-2.71%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥5.17bn

FY2017FY2025

Net income

CN¥2.18bn

FY2017FY2025

Free cash flow

CN¥2.14bn

FY2017FY2025

Shareholders' equity

CN¥6.50bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥5.17bnCN¥3.56bnCN¥2.02bnCN¥791.0mCN¥530.1mCN¥560,887CN¥629,723CN¥4.6mCN¥7.7m
Gross profitCN¥5.17bnCN¥3.39bnCN¥1.91bnCN¥743.9mCN¥500.1mCN¥399,193CN¥359,290CN¥4.4mCN¥7.5m
Research and developmentCN¥413.4mCN¥314.5mCN¥313.1mCN¥191.8mCN¥222.6mCN¥178.0mCN¥162.0mCN¥92.5mCN¥37.9m
Operating incomeCN¥2.57bnCN¥1.63bnCN¥657.7mCN¥127.8mCN¥21.8m−CN¥310.5m−CN¥393.5m−CN¥98.3m−CN¥38.8m
Net incomeCN¥2.18bnCN¥1.43bnCN¥644.2mCN¥130.5mCN¥18.3m−CN¥310.5m−CN¥397.5m−CN¥97.4m−CN¥38.9m
Diluted earnings per share4.863.201.440.290.04-0.78-1.10-0.22-0.09

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥7.90bnCN¥5.92bnCN¥4.38bnCN¥3.44bnCN¥3.13bnCN¥2.99bnCN¥1.33bnCN¥375.0mCN¥508.6m
Cash and short-term investmentsCN¥3.28bnCN¥3.35bnCN¥2.28bnCN¥2.04bnCN¥2.24bnCN¥2.59bnCN¥947.0mCN¥128.6mCN¥58.9m
Total liabilities−CN¥6.50bnCN¥633.3mCN¥394.2mCN¥255.1mCN¥157.0mCN¥109.0mCN¥144.0mCN¥304.0mCN¥127.4m
Debt—CN¥1.3mCN¥1.8mCN¥2.0mCN¥5.4m—CN¥110.0mCN¥125.0mCN¥60.0m
Shareholders' equityCN¥6.50bnCN¥5.28bnCN¥3.98bnCN¥3.19bnCN¥2.97bnCN¥2.88bnCN¥1.18bnCN¥71.0mCN¥381.3m
Shares outstanding449m447m449m452m478m401m360m449m449m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operationsCN¥2.32bnCN¥1.57bnCN¥674.6mCN¥91.6mCN¥29.3m−CN¥196.7m−CN¥259.4m−CN¥97.3mCN¥10.1m
Capital spending−CN¥186.0m−CN¥270.2m−CN¥67.9m−CN¥143.8m−CN¥192.2m−CN¥88.5m−CN¥89.4m−CN¥36.0m−CN¥1.4m
Free cash flowCN¥2.14bnCN¥1.30bnCN¥606.8m−CN¥52.2m−CN¥163.0m−CN¥285.2m−CN¥348.7m−CN¥133.2mCN¥8.7m
Dividends paid−CN¥360.0m−CN¥292.5m———−CN¥1.2m−CN¥33.4m−CN¥4.5m−CN¥4.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.74bnCN¥1.58bnCN¥1.44bnCN¥1.36bnCN¥1.28bnCN¥1.10bnCN¥1.02bnCN¥957.0m
Gross profitCN¥1.65bnCN¥1.50bnCN¥1.56bnCN¥1.33bnCN¥1.22bnCN¥1.06bnCN¥961.8mCN¥929.0m
Operating incomeCN¥1.04bnCN¥723.3mCN¥658.7mCN¥661.8mCN¥771.8mCN¥477.1mCN¥434.8mCN¥486.6m
Net incomeCN¥904.7mCN¥636.0mCN¥565.5mCN¥564.5mCN¥640.7mCN¥410.5mCN¥366.9mCN¥406.8m
Diluted earnings per share2.021.421.261.261.430.910.820.91
Cash from operations———CN¥670.0mCN¥735.0mCN¥392.0mCN¥329.0mCN¥506.0m
Capital spending−CN¥10.0m−CN¥8.0m−CN¥43.0m−CN¥63.0m−CN¥21.0m−CN¥57.0m−CN¥36.0m−CN¥179.0m
Free cash flow———CN¥607.0mCN¥714.0mCN¥335.0mCN¥293.0mCN¥327.0m
Total assetsCN¥9.44bnCN¥8.59bnCN¥7.90bnCN¥7.26bnCN¥6.98bnCN¥6.23bnCN¥5.92bnCN¥5.43bn
Cash and short-term investments——CN¥3.28bnCN¥3.28bnCN¥3.78bnCN¥3.65bnCN¥3.35bnCN¥3.03bn
Debt———CN¥1.7m————
Shareholders' equityCN¥8.46bnCN¥7.74bnCN¥6.50bnCN¥6.50bnCN¥6.13bnCN¥5.64bnCN¥5.28bnCN¥4.86bn

Financial ratios

Data as of 19 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin100.0%95.3%94.5%94.0%94.3%71.2%—
Operating margin49.7%45.9%32.6%16.2%4.1%-55350.1%—
Net margin42.2%40.2%31.9%16.5%3.4%-55361.4%—
Return on equity33.6%27.1%16.2%4.1%0.6%-10.8%—
Return on assets27.6%24.2%14.7%3.8%0.6%-10.4%—
Free cash flow yield5.7%4.2%1.7%0.5%0.5%-0.3%—
Revenue growth45.4%76.3%155.1%49.2%94410.0%-10.9%—
Earnings growth52.6%122.0%393.5%614.2%-105.9%-21.9%—
Current ratio5.18x6.96x7.46x8.98x15.21x24.58x—
Debt to equity—0.00x0.00x0.00x0.00x0.00x0.09x
Equity ratio82.2%89.3%91.0%92.6%95.0%96.4%—
Interest coverage19734.11x24784.73x3191.29x392.88x36.08x-260.26x—
R&D as a share of sales8.0%8.8%15.5%24.2%42.0%31728.8%—
Buybacks as a share of market value-0.3%0.3%0.7%5.5%-19.4%-11.3%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue87.0%520.8%—
Operating income171.9%——
Net income155.7%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin98.1%97.2%97.0%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings21.418.729.068.2—-36.7
Price to sales9.17.59.311.327.3—

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 1 Jun 2026.

FY2026FY2025FY2024
Paid in the year0.600.800.65

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.